Drug profile

The FDA adverse-event record for Glucosamine Hydrochloride + Chondroitin Sulfate + Methylsulfonylmethane

10 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Glucosamine Hydrochloride + Chondroitin Sulfate + Methylsulfonylmethane. See the species affected, top reactions, and outcomes below.

10
adverse-event reports
0.0%
death-coded share
Dog
most-reported species
7
Vomiting - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
10
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Glucosamine Hydrochloride + Chondroitin Sulfate + Methylsulfonylmethane

Administration Routes

UnknownOral

Species Affected

Dog 9
Cat 1

Most Affected Breeds

Crossbred Canine/dog 2
Terrier - Yorkshire 2
Mastiff 1
Terrier - Boston 1
Domestic Shorthair 1
Chihuahua 1
Bulldog - French 1
Boxer (German Boxer) 1

Most Reported Reactions

Vomiting 7
Diarrhoea 2
Foam in the mouth 2
Emesis 1
Lethargy (see also Central nervous system depression in 'Neurological') 1
Shivering 1
Ataxia 1
Emesis (multiple) 1
Elevated haemoglobin 1
Thrombocytosis 1
Weakness 1
Inappetence 1

Outcome Breakdown

Recovered/Normal
5 (50.0%)
Outcome Unknown
3 (30.0%)
Ongoing
2 (20.0%)

Glucosamine Hydrochloride + Chondroitin Sulfate + Methylsulfonylmethane Adverse Event Insights

10 reports name Glucosamine Hydrochloride + Chondroitin Sulfate + Methylsulfonylmethane; 0 recorded a death outcome (0.0% of reported events, not a population-level mortality rate). Active ingredient: Glucosamine Hydrochloride + Chondroitin Sulfate + Methylsulfonylmethane. Administration routes: Unknown, Oral.

By species: Dog (9 reports), Cat (1 reports). By breed: Crossbred Canine/dog (2), Terrier - Yorkshire (2), Mastiff (1).

Leading clinical signs: Vomiting (7), Diarrhoea (2), Foam in the mouth (2), Emesis (1). Outcome, 10 coded reports: Recovered/Normal leads at 50.0%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.